A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

128 sites for NCT04607421

BRAF V600E

Colorectal Carcinoma

cetuximab, +3 more drugs

chemotherapy, +1 more type

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

826 sites for NCT02465060

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

78 sites for NCT02693535

AKT1 Mutation, +128 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +19 more conditions

abemaciclib, +23 more drugs

immunotherapy, +1 more type

Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION

1 site for NCT04901988

BRAF V600E, +6 more biomarkers

Cutaneous Melanoma

nivolumab, +1 more drug

immunotherapy

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

60 sites for NCT04657991

BRAF V600E, +1 more biomarker

Cutaneous Melanoma

binimetinib, +2 more drugs

immunotherapy, +1 more type

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

109 sites for NCT03915951

BRAF V600E

Non-Small Cell Lung Carcinoma

binimetinib, +1 more drug

targeted therapy

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

84 sites for NCT03224767

BRAF V600E

Papillary Craniopharyngioma

cobimetinib, +1 more drug

targeted therapy

ITIL-168 in Advanced Melanoma

10 sites for NCT05050006

BRAF V600A, +6 more biomarkers

Cutaneous Melanoma

ITIL-168

cellular therapy, +1 more type

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

19 sites for NCT04949113

BRAF V600E, +1 more biomarker

Cutaneous Melanoma, +1 more condition

dabrafenib, +4 more drugs

immunotherapy, +2 more types

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

9 sites for NCT05039177

BRAF V600E, +2 more biomarkers

Colorectal Carcinoma

cetuximab, +3 more drugs

targeted therapy

A Study of Sasanlimab With Other Therapies in People With Non-small Cell Lung Cancer

41 sites for NCT04585815

BRAF V600E

Non-Small Cell Lung Carcinoma

axitinib, +4 more drugs

immunotherapy, +1 more type

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

35 sites for NCT04591431

AKT1 Amplification, +59 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +19 more drugs

immunotherapy, +1 more type